Nature Medicine publishes Helus Pharma Phase 2a trial of SPL026 in major depressive disorder

Nature Medicine has published Helus Pharma's randomized, placebo-controlled Phase 2a trial of SPL026 in major depressive disorder; the company's news release also includes forward-looking statements about other development programs and plans, including an anticipated topline readout for HLP004 in Q1 2026.

Nature Medicine has published Helus Pharma's randomized, placebo-controlled Phase 2a trial of SPL026 in major depressive disorder. The publication is presented as part of a company news release. That release includes standard forward-looking statements and cautions about risks and uncertainties. It also references other programs and development plans, including a scheduled topline data readout for HLP004 in generalized anxiety disorder in Q1 2026. Key points: - Nature Medicine published Helus Pharma's randomized, placebo-controlled Phase 2a trial of SPL026 in major depressive disorder. - The company's news release included forward-looking statements and noted that such statements are subject to risks and uncertainties. - The release mentions an anticipated topline data readout from a Phase 2 study evaluating HLP004 in generalized anxiety disorder in Q1 2026. - The article mentions SPL026 as a potentially more cost-effective treatment for clinical depression, presented as the company's claim. - The release describes the company's plans to develop novel serotonergic agonist molecules, proprietary drug discovery platforms, drug delivery systems, novel formulations and treatment regimens for mental health conditions. Summary: The publication reports the Phase 2a SPL026 trial and reiterates the company's forward-looking development plans. The release also notes an expected topline readout for HLP004 in GAD scheduled for Q1 2026. The broader impact and next regulatory or clinical steps are undetermined at this time.